
Please try another search
ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Name | Age | Since | Title |
---|---|---|---|
Alan M. Lotvin | 63 | 2022 | Independent Director |
Brian J. G. Pereira | 66 | 2022 | Independent Director |
Bruce Culleton | 56 | 2023 | CEO & Director |
Jose Ignacio Jimenez Santos | 49 | - | Independent Director |
Jennifer A. Fox | 53 | 2022 | Independent Director |
Uma Sinha | 67 | 2022 | Independent Director |
Pablo Gerardo Legorreta | 60 | - | Chairman of the Board |
William F. Doyle | 63 | 2022 | Lead Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review